{'fraction_non_alphanumeric': 0.015070921985815602, 'fraction_numerical': 0.008865248226950355, 'mean_word_length': 5.272222222222222, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Imminent risk of a global shortage of heparin caused by the African Swine Fever afflicting the Chinese pig herd

Most of the unfractionated and low‐molecular‐weight heparins available worldwide are produced by Chinese companies from porcine mucosa. China is the world′s largest producer of pork and thus has plenty of raw material to produce heparins. However, the deadly African Swine Fever (ASF) outbreaks afflicting China since August 2018 may cause extensive losses to the pig herd, with serious consequences for the global supply of heparins. In 2008, a sudden shortage of heparin's raw material resulting from a viral disease in Chinese pigs prompted adulterations responsible for 80 deaths and hundreds of adverse events. This incident revealed the fragility of such a supply chain, which is mostly based on raw material from a single animal from a single country. A worldwide introduction of bovine mucosa heparins manufactured in different countries certainly is a feasible way to mitigate eventual shortages of these life‐saving anticoagulants caused by local veterinary problems such as the ASF threatening China now.